Pfizer’s Lyrica cleared for fibromyalgia


NEW YORK (AP) – Drug developer Pfizer Inc. said Thursday the Food and Drug Administration approved its drug Lyrica as a treatment for fibromyalgia, a widespread and chronic pain condition.

The drug is already approved as a diabetic nerve pain treatment. During the first quarter, Lyrica sales reached $395 million.

Pfizer said about 6 million Americans have fibromyalgia, which is characterized by chronic widespread pain and can cause poor sleep, stiffness and fatigue.

Shares of Pfizer rose 23 cents to close at $25.94.


Questions or comments about this story should be directed to Damian J. Troise at 212-621-7190

Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.


Please enter your comment!
Please enter your name here